- Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb).
- The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with chronic HBV.
- "The combination therapy achieved hepatitis B surface antigen (HBsAg) knockdown of more than 3 log10 IU/mL, an impressive result, particularly when compared to other combination and monotherapies studies, the analyst writes.
- The analyst says that the positive outcome has increased confidence in the program.
- The analyst views Vir & Alnylam as emerging as leaders in the chronic HBV treatment space estimated to exceed $100 billion in aggregate revenues over the next 15 years.
- The update on the Emergency Use Authorization (EUA) for sotrovimab, a monoclonal antibody (mAb) antiviral for early-stage COVID-19, can dent the enthusiasm.
- Related: Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here.
- Ahead of trial readouts amid upside potential on the HBV program in 2H22 and 2023, HC Wainwright reiterates a Buy rating and the price target of $200 on the stock.
- Price Action: VIR shares are down 3.12% at $19.72 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
VIR
HC Wainwright
Hepatitis
Nasdaq
Alnylam Pharmaceuticals Inc
FDA
Vir Biotechnology Inc
Covid-19
biotechnology
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks